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Abstract
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Estrogens are potent and efficacious neuroprotectants both in vitro and in vivo in a variety of
models of neurotoxicity. We determined the structural requirements for neuroprotection in an in
vitro assay using a panel of more than 70 novel estratrienes, synthesized to reduce or eliminate
estrogen receptor (ER) binding. We observed that neuroprotection could be enhanced by as much
as 200-fold through modifications that positioned a large bulky group at the C2 or C4 position of
the phenolic A ring of the estratriene. Further, substitutions on the B, C or D rings either reduced
or did not markedly change neuroprotection. Collectively, there was a negative correlation between
binding to ERs and neuroprotection with the more potent compounds showing no ER binding. In
an in vivo model for neuroprotection, transient cerebral ischemia, efficacious compounds were
active in protection of brain tissue from this pro-oxidant insult. We demonstrated that these nonfeminizing estrogens engage in a redox cycle with glutathione, using the hexose monophosphate
shunt to apply cytosolic reducing potential to cellular membranes. Together, these results
demonstrate that non-feminizing estrogens are neuroprotective and protect brain from the
induction of ischemic- and Alzheimer’s disease (AD)-like neuropathology in an animal model.
These features of non-feminizing estrogens make them attractive compounds for assessment of
efficacy in AD and stroke, as they are not expected to show the side effects of chronic estrogen
therapy that are mediated by ER actions in the liver, uterus and breast.
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1. Introduction
1.1 Need for non-feminizing estrogens
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Menopause, in which a human female transitions to reproductive senescence, occurs during
the fifth decade of life among women (Timiras et al., 1995). This transition is characterized
by depleted ovarian follicles, declines in naturally circulating levels of sex hormones, such
as estrogens and progesterone, and a dysregulation of gonadotrophin feedback loops marked
by increasing levels of follicular stimulating hormone and lutenizing hormone (Rannevik et
al., 1995). Further, menopause is associated with hot flashes, urogenital atrophy, cognitive
decline (specifically learning and memory), and other symptoms that reduce quality of life
(Freedman, 2002; Sherwin & Henry, 2008). To alleviate these symptoms, estrogencontaining hormone therapy (HT) is given. Premarin® (conjugated equine estrogens), a
purified pregnant mare urine compound first developed by Wyeth, is the most widely used
estrogen-based menopausal HT in North America (Hersh et al., 2004) although a plethora of
other estrogen-containing treatment options exist as well (Sood et al., 2014). Despite these
treatments showing attenuation of undesirable menopausal symptoms (Sood et al., 2014) and
possible protection against brain aging and injury (Engler-Chiurazzi et al., 2016a), recent
comprehensive studies have demonstrated that in older women, chronic exposure to
feminizing estrogens alone or in combination with a synthetic progestin leads to an increase
in pro-thrombotic and pro-mitotic side effects (Manson et al., 2003; Wassertheil-Smoller et
al., 2003; Anderson et al., 2004). These chronic toxicities of feminizing estrogens are
mediated by the effects of persistent estrogen exposure in estrogen responsive tissues, like
the liver, uterus, and breast. This, combined with the controversial findings of the Women’s
Health Initiative regarding the potential increased risk for adverse outcomes among
reproductively senescent women taking HT has spurred an intense debate as to whether
estrogen-containing HTs should continue to be administered for treatment of menopausal
symptoms and brain aging. Given that approximately half of the aging adult population is
female, there is an important medical need to develop novel treatments for the menopausal
transition and aging processes with a more acceptable risk-to-benefit ratio.
1.2. Neuroprotective effects of estrogens

Author Manuscript

We were among the first research groups to document the beneficial actions of estrogens on
the central nervous system (reviewed in Engler-Chiurazzi et al., 2016b). We first
demonstrated potent neuroprotective activity of the feminizing estrogen, 17β-estradiol (17βE2), in 1994 (Bishop & Simpkins, 1994). Since then, the neuroprotective effects of
feminizing estrogens have been confirmed using neuronal cultures and primary cells against
a variety of toxicities including serum deprivation (Green et al., 1997a; Green et al., 1997b),
β-amyloid toxicity (Green et al., 1998; Pike, 1999), and oxidative stress (Behl et al., 1995;
Goodman et al., 1996; Sawada et al., 1998; Sawada et al., 2000)), among others, in
hippocampal, amygdala, cortical and mesencephalic neurons (for review, please see Green &
Simpkins, 2000; Garcia-Segura et al., 2001; Lee & McEwen, 2001). Similarly, in vivo
feminizing estrogens have been shown to enhance cognitive outcomes (Engler-Chiurazzi et
al., 2016a). As well, in in vivo animal models of brain injury, feminizing estrogens impart
protection in models of cerebral ischemia (Simpkins et al., 1997; Dubal et al., 1998; Yang et
al., 2000), following kainic acid treatment (Azcoitia et al., 1998), and in contusion injury
Exp Gerontol. Author manuscript; available in PMC 2018 August 01.
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models (Nakamizo et al., 2000; Gatson et al., 2012). Indeed, in stroke, the protective effects
of estrogens are seen in a variety of models including transient and permanent middle
cerebral artery occlusion models (Simpkins et al., 1997; Alkayed et al., 1998; Dubal et al.,
1998; Perez et al., 2005b), global forebrain ischemia models (Sudo et al., 1997),
photothrombotic focal ischemia models (Fukuda et al., 2000), and glutamate-induced focal
cerebral ischemia models (Mendelowitsch et al., 2001). The protection afforded by estrogens
is seen in rats, mice, and gerbils (Simpkins et al., 1997; Culmsee et al., 1999; Chen et al.,
2001) and in adult and middle-aged female rats, as well as in reproductively senescent
female rats (Wise et al., 2001). This protection is seen even in the presence of diabetes and
hypertension (Carswell et al., 2000; Toung et al., 2000). Similarly, the neuroprotective
effects of estrogens are observed against subarachnoid hemorrhage (Yang et al., 2001).
Finally, the neuroprotective actions of estrogen are also seen in males (Hawk et al., 1998;
Toung et al., 1998). Collectively, potent estrogen protection in these model systems suggest
that this steroid hormone may play an important role in preserving neurons in the face of a
variety of insults and represents an important therapeutic target for alleviating brain aging
and disease. However, given the potential for undesirable peripheral activity of feminizing
estrogens, the development of novel estrogen analogues that act in brain but not on
reproductive organs represents a promising future therapeutic option for the treatment of
brain aging.
1.3. Discovery of neuroprotection by non-feminizing estrogens
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In the process of conducting controled studies for the neuroprotective effects of 17β-E2, we
discovered that 17α-estradiol (17α-E2) was as potent as 17β-E2 in protection of neurons
from toxicity (Green et al., 1997a). 17α-E2 is a weak diastereomer of 17β-E2 and despite
the fact that 17β-E2 binds avidly to estrogen receptors (ERs) α and β and activates tissues in
a hormonally-responsive manner, 17α-E2 is biologically weak at both receptors. We went on
to show that the enantiomer of 17β-E2 (ent-17β-E2), which has identical physiochemical
properties as 17β-E2 except for interactions with other stereospecific molecules such as ERs
is potently neuroprotective (Green et al., 2001). ent-17β-E2 is reported to interact only
weakly with ERs (Chernayaev et al., 1975; Payne & Katzenellenbogen, 1979) and lacks
estrogenic effects on reproductive tissues in rodents (Terenius, 1968; 1971). Importantly,
although ent-17β-E2 exerts only slight anti-uterotrophic activity and can antagonize the
uterotrophic effects of 17β-E2 (Edgren & Jones, 1969; Terenius, 1971), ent-17β-E2 is still a
potent neuroprotectant (Green et al., 2001). These collective findings suggest that
neuroprotective effects of estrogens do not necessarily require action at the ER.

2. Structure-activity relationship among estrogens
Author Manuscript

In view of the observation that many of chronic estrogen treatment side-effects are likely due
to peripheral effects of orally administered estrogen preparations acting via known ERs
(Dubey et al., 2005; Maki, 2006; Salpeter et al., 2006; Coker et al., 2009; Resnick et al.,
2009), we sought to determine if non-feminizing estrogens could have the beneficial effects
of estrogens on brain protection, without the negative peripheral side effects of traditional
feminizing preparations. We undertook a series of studies to define the structure-activity
relationship among estrogen-like compounds for both neuroprotection and ER binding,
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based on our and other’s observations of a disparity between ER binding and
neuroprotection (Behl et al., 1997; Green et al., 1997b; Moosmann & Behl, 1999; Green et
al., 2001). We initially assessed over 70 synthetic estrogens to determine the structure
activity relationship among the compounds.
We defined that the minimal structural requirement for neuroprotection by estrogens is the
steroid A ring. Estrogens are the only class of steroids that have a phenolic A ring (Figure
1). Any modifications that eliminated the phenolic nature of the A ring completely
eliminated neuroprotective activity. These modifications included saturation of the A ring or
creation of a covalent bond with substituents through the 3 carbon oxygen.

Author Manuscript

Modifications of the D ring had little effect on the neuroprotective activity, including
changing the orientation of the 17 carbon hydroxyl group (as is the case with 17α-E2),
eliminating the 17 carbon hydroxyl group (estratriene-3-ol), or opening the D ring (Perez et
al., 2005a). The addition of polar groups in the B and C rings tended to reduce
neuroprotective activity of estrogens indicating that the center of the molecular requires
sufficient lipophilicity for neuroprotective activity (Perez et al., 2005a).
Finally, we observed a marked enhancement in neuroprotection with the addition of nonpolar group to the 2 and/or 4 carbons of the A ring (Perez et al., 2005a). One particularly
potent non-feminizing estrogen is ZYC-26, which has a large adamantly group on the 2
carbon and a methyl group on the 4 carbon (Figure 2).
When compounds were categorized by their binding affinity to ERα, we observed the
expected positive correlations with ERβ binding (Figure 3) but a negative correlation with
neuroprotective activity and lipid peroxidation (Figure 3).
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Collectively these structure-activity relationships argue for a neuroprotective mechanism(s)
that do not require action at the classical ERs. As such, we began a program of research to
determine the mechanism(s) by which non-feminizing estrogens are potently
neuroprotective.

3. Mechanism of non-feminizing estrogen neuroprotection
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Two observations suggested a potential mechanism by which non-feminizing estrogens
could be potently neuroprotective. First, the need for the estrogen molecule to avoid polar
groups on the B and C rings suggested that their interaction with lipid membranes was a
critical component of their neuroprotective activity. Given the high lipophilicity of estrogens,
most estrogens are associated with lipid membranes. Indeed, we have shown that estrogens
insert into lipid bilayers and that the presence of an adamantyl group at the C-2 position
affects the position of the A ring 3-hydroxyl group such that it is possible to detect an
orientation that would bring it into close proximity to the double bonds of membrane lipids;
a position that is optimal for terminating lipid peroxidation (Cegelski et al., 2006).
Second, we demonstrated that 17β-E2, 17α-E2, and estratriene-3-ol all synergizes with the
aqueous soluble antioxidant, glutathione to result in a 400-fold enhancement of the
neuroprotective activity of both feminizing and non-feminizing estrogens (Green et al.,
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1998). This suggests that lipid resident estrogens can interact with soluble cytosolic
antioxidants to halt an oxidative/inflammatory cellular cascade and achieve neuroprotection.
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We then assessed the possible redox cycling of estrogens with glutathione using human
erythrocytes (Dykens et al., 2004). Human erythrocytes (RBCs) lack mitochondria and
nuclei, making them a useful model to assess estrogens for assessing the redox potential of
non-feminizing estrogens. In this model, the hexose monophosphate shunt (HMS) generates
NADPH, which serves to reduce glutathione (GSH) from oxidized glutathione (GSSG),
allowing us to test the extent to which estrogens enhance the activity of this redox cycle.
With H2O2 exposure, the HMS is activated. In the presence of either 17β-E2 or 17α-E2, an
approximate doubling in HMS activity was observed (Figure 4). The potent neuroprotectant,
ZYC-3 increased HMS activity about 3-fold, but the inactive compound, ZYC-23 did not
affect HMS activity (Figure 4). These results indicate that estrogens are able to tap the large
reducing potential of the HMS, and through NADPH-induced reduction of GSSH to GSH,
and able to apply this reducing potential to lipid membranes using estrogens as a mediator.

4. Summary and Conclusions
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The present series of studies provide evidence that synthetic estrogens that do not interact
with ERs are potent neuroprotectants, likely working through a redox cycle that involves
glutathione and the HMS. The neuroprotection depends on a phenolic A ring and potency is
enhanced through aliphatic substituents on the 2 and/or 4 carbons of the estrogen molecule.
These compounds avoid ERα and ERβ, and as such are candidates for chronic therapy
aimed at preserving the brain from insults sustained by diseases, like AD, or more acute
traumas, like stroke. However, of important clinical significance is that, despite the strong
supportive evidence for their neuroprotective actions, because these non-feminizing
estrogens impart these effects independent of the classical ERs, the known peripheral
benefits of estrogen-containing HTs, including on urogenital tract, bone, and cardiovascular
tissues when administered near to the time of menopause initiation (Freedman, 2002;
Gambacciani & Levancini, 2014; Hale & Shufelt, 2015), may not be observed. Thus, in
conclusion, non-feminizing estrogens represent a novel and effective therapeutic
intervention approach for the prevention of injury-induced neuropathology.
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Highlights
•

Estrogen neuroprotection can be independent of estrogen receptors

•

The phenolic A ring of estrogen molecule is essential to its neuroprotective
activity

•

Allophalic substitutions at the 2 and 4 carbon of the A ring enhance
neuroprotective potency

•

Non-feminizing estrogens represent a novel target for post-menopausal brain
aging

•

Yet, with these agents, peripheral estrogenic benefits will not be observed
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Structure of 17 β-E2. Letters denote the 4 rings of the molecule and numbers indicate the
carbons positions.
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Figure 2.

Structure of 2-(1-Adamantyl)-4 methyl-3-hydroxyestra-1, 3, 5(10)-trien-17-one (ZYC-26).
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Figure 3.

Relationship among ER binding, neuroprotective activity and lipid peroxidation among
estrogens. All activities were categorized by ERα binding affinity and we observed a
marked negative relationship between ERα binding and neuroprotection in 4 assays of
neurotoxicity. GLUT indicated glutamate toxicity at 10 and 20 mM concentrations of
glutamate. IAA indicated indolacetic acid at 20 and 40 mM concentrations (IAA). TBARs
indicated thiobarbituric acid reactive substances (TBARs). Reproduced from Perez et al.,
2006, with permission.
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Figure 4.
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Carbon flux through the hexose monophosphate shunt in normal human erythrocytes
(RBCs). In the absence of an oxidative insult, the compounds have no effect on HMS flux.
However, exposure to 10 mM H2O2 significantly increases HMS flux in untreated control
RBCs. Treatment with the indicated compounds at 1 mM for 10 min prior to addition of 0.3
mCi 14C-U-glucose results in varying increases in HMS flux, with 17β-E2 and 17α-E2,
showing comparable responses. ZYC-3 significantly increased HMS flux over the estrogens,
and ZYC-23, a non-neuroprotective negative control, yields HMS flux rates
indistinguishable from untreated controls. Means not significantly different at P < 0.05
(Bonferroni), share superscripts; ANOVA F = 22.18, * P < 0.0001. Adapted and reprinted
with permission from Dykens et al., 2004
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